MDACC Study No:2007-0865 ( NCT No: NCT00480025)
Title:A Double- Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as Adjuvant therapy in Patients with Resectable MAGE-A3-Positive Non Small Cell Lung Cancer. (GSK Study # 109493)
Principal Investigator:David C. Rice
Treatment Agent:MAGE-3
Study Status:Terminated
Study Description:The goal of this research study is to learn if a tumor that has regrown after
treatment with MAGE-A3 ASCI or a new tumor that has formed after treatment with
MAGE-A3-ASCI also produces the MAGE-A3 protein. Researchers also want to learn
whether the cancer has become resistant to the MAGE-A3 ASCI or whether the
cancer changed (lost MAGE-A3 production).
Hide details for General InformationGeneral Information

Disease Group:Lung
Phase of Study:Phase III
Treatment Agents:MAGE-3
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:Not applicable.
Supported By:GlaxoSmithKline
Return Visit:On the day the drug will be administered, 3 weeks, 6 weeks, 9 weeks and 12
weeks after the first drug administration; then every three months for the
remaining 8 drug administration.
Home Care:None

Hide details for Study Contact InformationStudy Contact Information

Physician Name:David C. Rice
Dept:Thoracic & Cardiovascular
For Clinical Trial Enrollment:713-563-9155
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults